Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

W6QK ACC-APG

Contract Value

Not provided

Codes & Classification
Solicitation Number

W911SR-26-9-CADENCC

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AC13

Additional Details
Set Aside

NONE

Place of Performance

Frederick, Maryland, UNITED STATES

SourceSAM
Documents3
The Department of the Army, through the Army Contracting Command’s Edgewood Contracting Division at Fort Detrick, Maryland, has issued a presolicitation notice for the Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC) initiative. This procurement, identified under RPP Number W911SR-26-R-CADENCC and NAICS Code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), seeks to establish an advanced enabling capability to accelerate clinical trial startup and enhance CBRN (Chemical, Biological, Radiological, and Nuclear) defense readiness. The CADENCC program is managed by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRN Defense), specifically under the Joint Project Lead Enabling Technologies (JPL ET). The primary objective is to develop and implement a networked infrastructure that supports rapid initiation of clinical trials through the use of Master Protocols, innovative technologies for decentralized trial operations, and advanced data collection and analysis methods. Additionally, the program aims to establish a pre-positioned clinical trial site network to ensure readiness for CBRN defense scenarios. The scope of work encompasses the development and execution of Phase I and Phase II clinical trials focused on pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and early treatment products, including those potentially governed by the FDA’s Animal Rule. The anticipated outcome is the creation of a robust, scalable clinical trial capability that can be rapidly mobilized in response to emerging CBRN threats, thereby supporting the Department of Defense’s mission to field safe and effective medical countermeasures. This opportunity is being solicited under the authority of 10 USC 4022, Other Transaction Authority (OTA), specifically for prototype projects. The government intends to use this mechanism to foster innovation and agility in the development and demonstration of new technologies and processes. Successful prototype performers may be eligible for follow-on production contracts or other transaction agreements, provided they meet the requirements and complete the prototype phase as stipulated. Key requirements and evaluation criteria for this procurement include: - Demonstrated technical merit, with clear, feasible, and state-of-the-art plans, methods, and schedules. - Direct military and program relevance, supporting the development of medical CBRN countermeasures and reducing programmatic risk. - Availability of funds, with the understanding that awards are contingent upon budgetary priorities and the evolving needs of the program. - Technology Readiness Level (TRL) of 4 or higher. - Clear, logical, and innovative project objectives. - Compliance with FDA regulations, including current Good Manufacturing Practice (cGMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP). - Alignment with other U.S. Government requirements and avoidance of unnecessary duplication. - Qualifications and experience of key personnel, particularly the Project Manager and technical staff. - Adequacy of facilities and equipment to support the proposed work. - Justified and reasonable budget/cost proposals. - Demonstrated past performance on relevant projects. - Overall best value to the government, based on an integrated assessment of technical and cost factors. The contracting entity for this opportunity is W6QK ACC-APG, a federal office under the Department of Defense and the Department of the Army. The place of performance is Frederick, Maryland. There are no set-aside requirements for this procurement; it is open to all qualified entities. Offerors must be registered in the System for Award Management (SAM) prior to award and maintain their registration throughout the contract period. All submissions must adhere to the specified format and page limits, and must be received by the stated deadline—1500 hours on 17 September 2026. Interested parties are encouraged to review the attached Statement of Objectives (SOO) for detailed requirements and to direct any questions to the designated points of contact: Hunter T. Robinson ([email protected]), Bianca Batista ([email protected]), and Keith D. Pereira ([email protected]), no later than five business days before the closing date. This presolicitation notice is for planning purposes only and does not constitute a commitment by the government to award an agreement. All costs associated with proposal preparation are the responsibility of the offeror. The government reserves the right to negotiate, select, and award agreements based on the best interests of the program and the availability of funds. For further details and to access the full notice and attachments, please refer to the official posting on SAM.gov (Opportunity ID: 0a35e2635f7e4b36a68f1637e14450ee).